We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of the X-SIZER Thrombectomy Device with Adjunct Abciximab During Primary Angioplasty and Stenting for ST-Segment Elevation Myocardial Infarction.
- Authors
Low, Adrian F.; Lim, Yean-Teng; Teo, Swee-Guan; Budiono, Bambang; Sutandar, Antono; Tan, Huay-Cheem
- Abstract
Objective: To evaluate the safety and efficacy of the X-SIZER thrombectomy device versus the use of abciximab during primary angioplasty for acute ST-elevation myocardial infarction (STEMI). Design: Retrospective analysis of patients undergoing primary angioplasty for STEMI from October 2000 to December 2002 using the X-SIZER thrombectomy device versus abciximab. Setting: National University Hospital, Singapore. Patients: Out of 79 patients, 44 underwent X-SIZER use, while 35 received adjunct abciximab. Both groups were similarly represented with regards to age, gender, risk factors, target vessel site/diameter, cardiogenic shock, and onset of chest pain to procedure time. The infarct-related artery was occluded in 88.6% in both groups. Interventions: A 2-mm X-SIZER was used in 34/44 (77.3%), while a 1.5-mm device was used in the remainder. Final TIMI 3 flow was obtained in 38/44 (86.4%) in the X-SIZER group compared to 26/35 (74.3%) in the abciximab group (P = 0.175). Main Outcome Measures: Coronary TIMI flow rate, electrocardiogram (ECG) resolution, slow flow/no reflow phenomenon, and patient outcome (death, cardiac failure, or repeat revascularization) at 1 month. Results: ECG resolution and slow flow/no reflow were better in the X-SIZER group (77.3% vs 54.3%, P = 0.031; 9.1% vs 25.7%, P = 0.047, respectively). Patient outcome at 1 month was, however, not significantly different (18.2% vs 17.1%, P = 0.904, respectively, for X-SIZER and abciximab). Conclusion: X-SIZER thrombectomy during primary percutaneous coronary intervention for thrombus-laden STEMI is a safe and effective strategy. When compared to patients receiving abciximab, it was associated with improved ECG resolution, less slow flow/no reflow and a trend to better TIMI 3 flow. (J Interven Cardiol 2005;18:267–273)
- Subjects
MEDICAL equipment; MYOCARDIAL infarction; ANGIOPLASTY; CORONARY disease; ELECTROCARDIOGRAPHY; CARDIOLOGY
- Publication
Journal of Interventional Cardiology, 2005, Vol 18, Issue 4, p267
- ISSN
0896-4327
- Publication type
Article
- DOI
10.1111/j.1540-8183.2005.00044.x